In vitro studies in OVCAR5 cells were performed as previously described in (13 (link)). OVCAR5 cells (ATCC) were seeded in 96-well plates (Corning Costar Cat.# 3917) in media containing 2.5% FBS (Charles River Laboratories). After 48 hours, paclitaxel (Sigma-Aldrich) ± 100 nmol/L dexamethasone (Sigma-Aldrich) ± 450 nmol/L relacorilant were added. After another 72 hours, 100 μL of Cell Titer-Glo (Promega) reagent was added to each well and luminescence was quantified on the Synergy II microplate reader (BioTek). Data were normalized to controls, either equivalent volumes of dimethyl sulfoxide or empty wells. A non-parametric t test was conducted to compare normalized percentage of viability at 1,000 nmol/L paclitaxel, 100 nmol/L dexamethasone, ± 450 nmol/L relacorilant using Microsoft Excel. Charles River Laboratories study number: e533.
Protocol detail
Paclitaxel Combination Therapy in OVCAR5 Cells
In vitro studies in OVCAR5 cells were performed as previously described in (13 (link)). OVCAR5 cells (ATCC) were seeded in 96-well plates (Corning Costar Cat.# 3917) in media containing 2.5% FBS (Charles River Laboratories). After 48 hours, paclitaxel (Sigma-Aldrich) ± 100 nmol/L dexamethasone (Sigma-Aldrich) ± 450 nmol/L relacorilant were added. After another 72 hours, 100 μL of Cell Titer-Glo (Promega) reagent was added to each well and luminescence was quantified on the Synergy II microplate reader (BioTek). Data were normalized to controls, either equivalent volumes of dimethyl sulfoxide or empty wells. A non-parametric t test was conducted to compare normalized percentage of viability at 1,000 nmol/L paclitaxel, 100 nmol/L dexamethasone, ± 450 nmol/L relacorilant using Microsoft Excel. Charles River Laboratories study number: e533.
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization : University of California, San Francisco
Other organizations : Corcept Therapeutics (United States), University of Chicago, HonorHealth
Top 5 similar protocols
Variable analysis
independent variables
- Paclitaxel (Sigma-Aldrich)
- Dexamethasone (Sigma-Aldrich)
- Relacorilant
- Cell viability
- OVCAR5 cells (ATCC)
- Media containing 2.5% FBS (Charles River Laboratories)
- Cell Titer-Glo (Promega) reagent
- Synergy II microplate reader (BioTek)
- Positive control: equivalent volumes of dimethyl sulfoxide
- Negative control: empty wells
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!